Dietary supplement use in cancer care: help or harm.
Identifieur interne : 003193 ( PubMed/Curation ); précédent : 003192; suivant : 003194Dietary supplement use in cancer care: help or harm.
Auteurs : Mary L. Hardy [États-Unis]Source :
- Hematology/oncology clinics of North America [ 0889-8588 ] ; 2008.
Descripteurs français
- KwdFr :
- Antioxydants (effets indésirables), Antioxydants (usage thérapeutique), Bouffées de chaleur (), Cachexie (), Compléments alimentaires (effets indésirables), Compléments alimentaires (utilisation), Essais contrôlés randomisés comme sujet (), Humains, Interactions médicaments-plantes, Lymphoedème (), Lésions radio-induites (), Maladies gastro-intestinales (), Neuropathies périphériques (), Phytothérapie, Préparations à base de plantes (effets indésirables), Préparations à base de plantes (usage thérapeutique), Radiothérapie (effets indésirables), Risque, Stomatite (), Thérapies complémentaires, Tumeurs (), Tumeurs (diétothérapie), Tumeurs (radiothérapie), Tumeurs (traitement médicamenteux).
- MESH :
- diétothérapie : Tumeurs.
- effets indésirables : Antioxydants, Compléments alimentaires, Préparations à base de plantes, Radiothérapie.
- radiothérapie : Tumeurs.
- traitement médicamenteux : Tumeurs.
- usage thérapeutique : Antioxydants, Préparations à base de plantes.
- utilisation : Compléments alimentaires.
- Bouffées de chaleur, Cachexie, Essais contrôlés randomisés comme sujet, Humains, Interactions médicaments-plantes, Lymphoedème, Lésions radio-induites, Maladies gastro-intestinales, Neuropathies périphériques, Phytothérapie, Risque, Stomatite, Thérapies complémentaires, Tumeurs.
English descriptors
- KwdEn :
- Antioxidants (adverse effects), Antioxidants (therapeutic use), Cachexia (therapy), Complementary Therapies, Dietary Supplements (adverse effects), Dietary Supplements (utilization), Gastrointestinal Diseases (chemically induced), Gastrointestinal Diseases (therapy), Herb-Drug Interactions, Hot Flashes (therapy), Humans, Lymphedema (therapy), Neoplasms (diet therapy), Neoplasms (drug therapy), Neoplasms (prevention & control), Neoplasms (radiotherapy), Neoplasms (therapy), Peripheral Nervous System Diseases (chemically induced), Peripheral Nervous System Diseases (therapy), Phytotherapy, Plant Preparations (adverse effects), Plant Preparations (therapeutic use), Radiation Injuries (therapy), Radiotherapy (adverse effects), Randomized Controlled Trials as Topic (statistics & numerical data), Risk, Stomatitis (therapy).
- MESH :
- chemical , adverse effects : Antioxidants, Plant Preparations.
- chemical , therapeutic use : Antioxidants, Plant Preparations.
- adverse effects : Dietary Supplements, Radiotherapy.
- chemically induced : Gastrointestinal Diseases, Peripheral Nervous System Diseases.
- diet therapy : Neoplasms.
- drug therapy : Neoplasms.
- prevention & control : Neoplasms.
- radiotherapy : Neoplasms.
- statistics & numerical data : Randomized Controlled Trials as Topic.
- therapy : Cachexia, Gastrointestinal Diseases, Hot Flashes, Lymphedema, Neoplasms, Peripheral Nervous System Diseases, Radiation Injuries, Stomatitis.
- utilization : Dietary Supplements.
- Complementary Therapies, Herb-Drug Interactions, Humans, Phytotherapy, Risk.
Abstract
Conventional wisdom generally recommends complete avoidance of all dietary supplements, especially during chemotherapy and radiation. This interdiction persists, in spite of high rates of dietary supplement use by patients throughout all phases of cancer care, and can result in patients' perceptions of physicians as negative, thus leading to widespread nondisclosure of use. A review of the clinical literature shows that some evidence for harm does exist; however, data also exist that show benefit from using certain well-qualified supplements. Physicians should increase their knowledge base about dietary supplement use in cancer and consider all of the data when advising patients. Strategies that are patient-centered and reflect the complete array of available evidence lead to more nuanced messages about dietary supplement use in cancer. This should encourage greater disclosure of use by patients and ultimately increase safety and efficacy for patients choosing to use dietary supplements during cancer care.
DOI: 10.1016/j.hoc.2008.04.012
PubMed: 18638690
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003193
Links to Exploration step
pubmed:18638690Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dietary supplement use in cancer care: help or harm.</title>
<author><name sortKey="Hardy, Mary L" sort="Hardy, Mary L" uniqKey="Hardy M" first="Mary L" last="Hardy">Mary L. Hardy</name>
<affiliation wicri:level="1"><nlm:affiliation>Simms/Mann-UCLA Center for Integrative Oncology, University of California at Los Angeles, 200 UCLA Medical Plaza, Suite 502 Los Angeles, CA 90095-9615, USA. mhardy@mednet.ucla.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Simms/Mann-UCLA Center for Integrative Oncology, University of California at Los Angeles, 200 UCLA Medical Plaza, Suite 502 Los Angeles, CA 90095-9615</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18638690</idno>
<idno type="pmid">18638690</idno>
<idno type="doi">10.1016/j.hoc.2008.04.012</idno>
<idno type="wicri:Area/PubMed/Corpus">003193</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003193</idno>
<idno type="wicri:Area/PubMed/Curation">003193</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003193</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Dietary supplement use in cancer care: help or harm.</title>
<author><name sortKey="Hardy, Mary L" sort="Hardy, Mary L" uniqKey="Hardy M" first="Mary L" last="Hardy">Mary L. Hardy</name>
<affiliation wicri:level="1"><nlm:affiliation>Simms/Mann-UCLA Center for Integrative Oncology, University of California at Los Angeles, 200 UCLA Medical Plaza, Suite 502 Los Angeles, CA 90095-9615, USA. mhardy@mednet.ucla.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Simms/Mann-UCLA Center for Integrative Oncology, University of California at Los Angeles, 200 UCLA Medical Plaza, Suite 502 Los Angeles, CA 90095-9615</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Hematology/oncology clinics of North America</title>
<idno type="ISSN">0889-8588</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antioxidants (adverse effects)</term>
<term>Antioxidants (therapeutic use)</term>
<term>Cachexia (therapy)</term>
<term>Complementary Therapies</term>
<term>Dietary Supplements (adverse effects)</term>
<term>Dietary Supplements (utilization)</term>
<term>Gastrointestinal Diseases (chemically induced)</term>
<term>Gastrointestinal Diseases (therapy)</term>
<term>Herb-Drug Interactions</term>
<term>Hot Flashes (therapy)</term>
<term>Humans</term>
<term>Lymphedema (therapy)</term>
<term>Neoplasms (diet therapy)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neoplasms (prevention & control)</term>
<term>Neoplasms (radiotherapy)</term>
<term>Neoplasms (therapy)</term>
<term>Peripheral Nervous System Diseases (chemically induced)</term>
<term>Peripheral Nervous System Diseases (therapy)</term>
<term>Phytotherapy</term>
<term>Plant Preparations (adverse effects)</term>
<term>Plant Preparations (therapeutic use)</term>
<term>Radiation Injuries (therapy)</term>
<term>Radiotherapy (adverse effects)</term>
<term>Randomized Controlled Trials as Topic (statistics & numerical data)</term>
<term>Risk</term>
<term>Stomatitis (therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antioxydants (effets indésirables)</term>
<term>Antioxydants (usage thérapeutique)</term>
<term>Bouffées de chaleur ()</term>
<term>Cachexie ()</term>
<term>Compléments alimentaires (effets indésirables)</term>
<term>Compléments alimentaires (utilisation)</term>
<term>Essais contrôlés randomisés comme sujet ()</term>
<term>Humains</term>
<term>Interactions médicaments-plantes</term>
<term>Lymphoedème ()</term>
<term>Lésions radio-induites ()</term>
<term>Maladies gastro-intestinales ()</term>
<term>Neuropathies périphériques ()</term>
<term>Phytothérapie</term>
<term>Préparations à base de plantes (effets indésirables)</term>
<term>Préparations à base de plantes (usage thérapeutique)</term>
<term>Radiothérapie (effets indésirables)</term>
<term>Risque</term>
<term>Stomatite ()</term>
<term>Thérapies complémentaires</term>
<term>Tumeurs ()</term>
<term>Tumeurs (diétothérapie)</term>
<term>Tumeurs (radiothérapie)</term>
<term>Tumeurs (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antioxidants</term>
<term>Plant Preparations</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term>
<term>Plant Preparations</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Dietary Supplements</term>
<term>Radiotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Gastrointestinal Diseases</term>
<term>Peripheral Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="diet therapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diétothérapie" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antioxydants</term>
<term>Compléments alimentaires</term>
<term>Préparations à base de plantes</term>
<term>Radiothérapie</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Cachexia</term>
<term>Gastrointestinal Diseases</term>
<term>Hot Flashes</term>
<term>Lymphedema</term>
<term>Neoplasms</term>
<term>Peripheral Nervous System Diseases</term>
<term>Radiation Injuries</term>
<term>Stomatitis</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antioxydants</term>
<term>Préparations à base de plantes</term>
</keywords>
<keywords scheme="MESH" qualifier="utilisation" xml:lang="fr"><term>Compléments alimentaires</term>
</keywords>
<keywords scheme="MESH" qualifier="utilization" xml:lang="en"><term>Dietary Supplements</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Complementary Therapies</term>
<term>Herb-Drug Interactions</term>
<term>Humans</term>
<term>Phytotherapy</term>
<term>Risk</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Bouffées de chaleur</term>
<term>Cachexie</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Interactions médicaments-plantes</term>
<term>Lymphoedème</term>
<term>Lésions radio-induites</term>
<term>Maladies gastro-intestinales</term>
<term>Neuropathies périphériques</term>
<term>Phytothérapie</term>
<term>Risque</term>
<term>Stomatite</term>
<term>Thérapies complémentaires</term>
<term>Tumeurs</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Conventional wisdom generally recommends complete avoidance of all dietary supplements, especially during chemotherapy and radiation. This interdiction persists, in spite of high rates of dietary supplement use by patients throughout all phases of cancer care, and can result in patients' perceptions of physicians as negative, thus leading to widespread nondisclosure of use. A review of the clinical literature shows that some evidence for harm does exist; however, data also exist that show benefit from using certain well-qualified supplements. Physicians should increase their knowledge base about dietary supplement use in cancer and consider all of the data when advising patients. Strategies that are patient-centered and reflect the complete array of available evidence lead to more nuanced messages about dietary supplement use in cancer. This should encourage greater disclosure of use by patients and ultimately increase safety and efficacy for patients choosing to use dietary supplements during cancer care.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18638690</PMID>
<DateCreated><Year>2008</Year>
<Month>07</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted><Year>2008</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2008</Year>
<Month>07</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0889-8588</ISSN>
<JournalIssue CitedMedium="Print"><Volume>22</Volume>
<Issue>4</Issue>
<PubDate><Year>2008</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Hematology/oncology clinics of North America</Title>
<ISOAbbreviation>Hematol. Oncol. Clin. North Am.</ISOAbbreviation>
</Journal>
<ArticleTitle>Dietary supplement use in cancer care: help or harm.</ArticleTitle>
<Pagination><MedlinePgn>581-617, vii</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hoc.2008.04.012</ELocationID>
<Abstract><AbstractText>Conventional wisdom generally recommends complete avoidance of all dietary supplements, especially during chemotherapy and radiation. This interdiction persists, in spite of high rates of dietary supplement use by patients throughout all phases of cancer care, and can result in patients' perceptions of physicians as negative, thus leading to widespread nondisclosure of use. A review of the clinical literature shows that some evidence for harm does exist; however, data also exist that show benefit from using certain well-qualified supplements. Physicians should increase their knowledge base about dietary supplement use in cancer and consider all of the data when advising patients. Strategies that are patient-centered and reflect the complete array of available evidence lead to more nuanced messages about dietary supplement use in cancer. This should encourage greater disclosure of use by patients and ultimately increase safety and efficacy for patients choosing to use dietary supplements during cancer care.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hardy</LastName>
<ForeName>Mary L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>Simms/Mann-UCLA Center for Integrative Oncology, University of California at Los Angeles, 200 UCLA Medical Plaza, Suite 502 Los Angeles, CA 90095-9615, USA. mhardy@mednet.ucla.edu</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Hematol Oncol Clin North Am</MedlineTA>
<NlmUniqueID>8709473</NlmUniqueID>
<ISSNLinking>0889-8588</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D028321">Plant Preparations</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002100" MajorTopicYN="N">Cachexia</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000529" MajorTopicYN="Y">Complementary Therapies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000656" MajorTopicYN="N">utilization</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D041743" MajorTopicYN="N">Herb-Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019584" MajorTopicYN="N">Hot Flashes</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D028321" MajorTopicYN="N">Plant Preparations</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011832" MajorTopicYN="N">Radiation Injuries</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013280" MajorTopicYN="N">Stomatitis</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>201</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>11</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18638690</ArticleId>
<ArticleId IdType="pii">S0889-8588(08)00064-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.hoc.2008.04.012</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003193 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003193 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:18638690 |texte= Dietary supplement use in cancer care: help or harm. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18638690" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |